曲妥珠单抗联合化疗治疗Her-2过表达转移性乳腺癌40例  

Trastuzumab Combined with Chemotherapy in the Treatment for 40 Cases with Her-2-overexpressing Metastatic Breast Cancer

作　　者：任庆[1] 伍靖武[1] 熊锐华[1] 周欣[1] 

机构地区：[1]中国人民解放军第181中心医院,广西桂林541002

出　　处：《肿瘤学杂志》2010年第3期175-177,共3页Journal of Chinese Oncology

摘　　要：[目的]观察曲妥珠单抗(trastuzumab)联合长春瑞滨(NVB)等化疗药物治疗Her-2过表达转移性乳腺癌患者的疗效和毒副反应。[方法]40例Her-2过表达转移性乳腺癌患者,其中Her(++)17例,Her(+++)23例。曲妥珠单抗初始剂量为4mg/kg,以后每周1次,剂量为2mg/kg,不少于6周。NVB25mg/m2,d1;DDP70mg/m2,d1～3。每21d为1个周期。[结果]总有效率为60%,其中CR6例,PR18例;主要毒副反应为Ⅲ～Ⅳ度粒细胞减少及发热;未观察到明显的心脏毒性。[结论]曲妥珠单抗联合NVB为主的化疗方案治疗Her-2过表达转移性乳腺癌可行,毒副反应可耐受。[Purpose] To investigate the effect and toxicity of trastuzumab combined with vinorelbine based chemotherapy for Her-2-overexpressing metastatic breast cancer.[Methods] Forty cases with Her-2-overexpressing metastatic breast cancer,17 cases with Her-2（＋＋） and 23 cases with Her-2（＋＋＋）.The initial dose of trastuzumab was 4mg/kg,then once per week with 2mg/kg,at least 6 weeks.The dose of vinorelbine was 25mg/m2,d1;cisplatin was 70mg/m2,d1～3,every 21 days as a cycle.[Results] The overall response rate was 60%,6 cases in CR and 18 cases in PR.The main toxicity was fever and neutropenia（grade Ⅲ～Ⅳ）.[Conclusion] Trastuzumab combined with vinorelbine-based chemotherapy for Her-2-overexpressing metastatic breast cancer is feasible and tolerable.

关 键 词：曲妥珠单抗 人类表皮生长因子受体-2 药物疗法 乳腺肿瘤 

分 类 号：R737.9[医药卫生—肿瘤]